Cost–effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain

AIM: To estimate the cost–effectiveness of treating postmenopausal osteoporosis (PMO) with weekly gastro-resistant risedronate 35 mg gastro-resistant tablets (RIS-GR), compared with weekly alendronate 70 mg tablets (ALN) in Spain. METHODS: A probabilistic analysis (second-order Monte Carlo simulatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Casado, Enrique, Rosas, José, Rubio-Terrés, Carlos, Rubio-Rodríguez, Darío, Boolell, Mitra, Arístegui, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690429/
https://www.ncbi.nlm.nih.gov/pubmed/37712635
http://dx.doi.org/10.57264/cer-2023-0115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690429/
https://www.ncbi.nlm.nih.gov/pubmed/37712635
http://dx.doi.org/10.57264/cer-2023-0115

Ejemplares similares